Insider

Vertex Pharmaceuticals Inc / MA

VRTX Health Care · 1 analysis · 15 expectations tracked

Vertex Pharmaceuticals Inc / MA reported $3.4B in revenue (+11.8% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 15 open management expectations for this company. 2 insider sales recorded. Its latest periodic filing added 2 new risk factors.

Mentioned in recent filings: Russia Tariffs

What changed

Company history

October 2026

VERTEX PHARMACEUTICALS INC / MA: 5 recorded developments from 1 official source in 2026-10.

  • 2026-10-20: Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals Incorporated. Source
  • 2026-10-20: The size of the Board was increased from ten to eleven members. Source
  • 2026-10-20: Daniel Brennan joined the Audit and Finance Committee of the Board. Source
  • 2026-10-20: Upon joining the Board, Daniel Brennan received a $400,000 restricted stock unit award. Source
  • 2026-10-20: The Company reported there are no transactions involving Mr. Brennan requiring report under Item 404(a) and no arrangement or understanding regarding his appointment to the Board. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC

LatestEarlierChange
Revenue quarter$3.4B$3.1B+11.8%
Operating income quarter$713M$1.2B-39.9%
Net income quarter$654M$1.1B-39.6%
Diluted EPS quarter$2.56$4.20-39.0%
Operating cash flow year to date$3.2B$3.1B+2.0%
Cash and cash equivalents balance$5B$5.1B-2.1%
Long-term debt balance$3.5B$0—

Next results expected around February 2, 2027 (estimate: the quarter ending about December 30, 2026 plus the 34 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

2.9Q4 '24*35.2%2.8Q1 '2522.7%3Q2 '2538.8%3.1Q3 '2538.6%3.2Q4 '25*37.8%3Q1 '2638.1%3.3Q2 '2637.4%3.4Q3 '2620.7%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Vertex Pharmaceuticals Inc / MA VRTX$3.4B+11.8%20.7%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Vertex plans to advance VX-017 into pivotal development.

    Said November 2, 2026 · Period named: 2027 · Source · Our article

    Not yet checked against later reports.

  • Vertex is on track to share results from the gMG study in the first half of 2027.

    Said November 2, 2026 · Period named: first half of 2027 · Source · Our article

    Not yet checked against later reports.

  • Vertex expects to advance VX-017 into pivotal development in 2027.

    Said November 2, 2026 · Period named: 2027 · Source · Our article

    Not yet checked against later reports.

  • The company plans to complete enrollment in the Phase 2 study of VX-993 in DPN.

    Said November 2, 2026 · Period named: by the end of 2026 · Source · Our article

    Not yet checked against later reports.

  • Vertex expects to complete enrollment in the atumelnant trial in the first quarter of 2027.

    Said November 2, 2026 · Period named: first quarter of 2027 · Source · Our article

    Not yet checked against later reports.

  • Vertex is on track to share interim results from the GALILEO study.

    Said November 2, 2026 · Period named: second half of 2026 · Source · Our article

    Not yet checked against later reports.

Show all (15)
  • Vertex plans for the Phase 3 trial of atumelnant in adults with CAH, with expectations to complete enrollment in the first quarter of 2027.

    Said November 2, 2026 · Period named: first quarter of 2027 · Source · Our article

    Not yet checked against later reports.

  • Raised full year 2026 total revenue guidance to $13.15 billion to $13.25 billion.

    Said November 2, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Vertex expects to complete dosing in the VX-670 trial for DM1 and share interim results.

    Said November 2, 2026 · Period named: second half of 2026 · Source · Our article

    Not yet checked against later reports.

  • Vertex expects to begin PALSONIFY launches in European markets in the second half of 2027.

    Said November 2, 2026 · Period named: second half of 2027 · Source · Our article

    Not yet checked against later reports.

  • The company expects $500 million or more in revenue from CASGEVY and JOURNAVX combined, and $40 million to $50 million in revenue from PALSONIFY.

    Said November 2, 2026 · Period named: Full Year 2026 · Source · Our article

    Not yet checked against later reports.

  • Vertex is on track to share data from the inaxaplin interim analysis in early 2027.

    Said November 2, 2026 · Period named: early 2027 · Source · Our article

    Not yet checked against later reports.

  • The company expects to begin launches for PALSONIFY in European markets.

    Said November 2, 2026 · Period named: second half of 2027 · Source · Our article

    Not yet checked against later reports.

  • The company plans to share results from the suzetrigine Phase 3 studies in DPN.

    Said November 2, 2026 · Period named: mid-2027 · Source · Our article

    Not yet checked against later reports.

  • The company plans to complete enrollment in both Phase 3 studies of suzetrigine in DPN.

    Said November 2, 2026 · Period named: by the end of 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 3, 2026 compared with the 10-Q filed August 4, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (2)

  • FDA’s review of our biologics license application for accelerated approval of povetacicept with an assigned PDUFA
  • anticipated potential of atumelnant, and that Crinetics will contribute to the diversity of our pipeline and support our

Dropped (6)

  • material adverse effect on our business. The Crinetics Acquisition may not be completed for a number of reasons, including
  • the need to satisfy customary closing conditions, the need for antitrust and/or other regulatory approvals, as well as potential
  • disputes or litigation that may arise. We provide no assurance that the Crinetics Acquisition will occur or that the closing

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 20, 2026Director or officer departure or appointment (8-K item 5.02)8-K
September 1, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Thornberry NancyPlanned sale 10b5-1 plan1,000—$547,860SEC
November 16, 2026Bhatia Sangeeta N.Planned sale 10b5-1 plan271—$148,470SEC
November 12, 2026Charles F Wagner JrSale 10b5-1 plan notice filed15,286$547.87$8,374,741SEC
November 6, 2026Reshma KewalramaniSale 10b5-1 plan notice filed11,866$531.53$6,307,135SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock23,803,111$12,444,504,450-1.3%Q3 2026
Capital Research Global Investors17,814,302$9,313,657,644-8.6%Q3 2026
State Street12,024,456$6,286,505,841+1.3%Q3 2026
Geode Capital Management6,081,969$3,165,506,588+1.1%Q3 2026
Wellington Management3,363,758$1,758,606,320+3.6%Q3 2026
Norges Bank (Norway's sovereign fund)2,971,681$1,476,123,103—Q2 2026
Fidelity (FMR)1,541,000$805,650,363+5.8%Q3 2026
Citadel Advisors1,032,674$539,892,294+102.3%Q3 2026
Millennium Management567,655$296,775,711+21.2%Q3 2026
Renaissance Technologies396,768$207,434,278+24.0%Q3 2026
Two Sigma Investments203,123$106,194,736-28.7%Q3 2026
Bridgewater Associates34,915$18,253,911+221.4%Q3 2026
D. E. Shaw & Co.5,631$2,943,944+81.4%Q3 2026
T. Rowe Price1,733,342$906,209+0.3%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.